The National Biomarker Development Alliance at Arizona State University has a mission to create the standards needed to support biomarker development and advance precision medicine.
The NBDA plans to create rules—such as best practices and standard operating procedures—for biomarker development that will be shared among stakeholders such as patient groups, researchers, and physicians. NBDA seeks to ultimately change the current dismal success rate of biomarker discovery, development and validation, according to a NBDA press release.
The Flinn Foundation is a financial supporter of NBDA, a non-profit organization that was announced Jan. 13 at the National Press Club in Washington D.C.
In addition, ASU and Dublin City University (DCU) in Dublin, Ireland, are joining together to create a new International School of Biomedical Diagnostics, which will offer the first degree program of its kind. The initiative aims to establish diagnostics as an independent discipline and will collaborate with NBDA.
For more information:
“Group aims for biomarker standards,” The Scientist, 1/14/14
“Launch of a Transformative Health Care Initiative: The National Biomarker Development Alliance,” NBDA Press Release, 1/13/14